// App-Quantinova.ai

e19040 : Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.

Researchers

Presenter

  • Ruben A. Mesa

Principal Investigators

  • Lysbeth Floden

  • Jeanne Palmer

  • Vikas Gupta

  • Donal P. Mclornan

  • Mary Frances McMullin

  • Jean-Jacques Kiladjian

  • Lynda M. Foltz

  • Uwe Platzbecker

  • Maria Laura Fox

  • Adam J. Mead

  • David M. Ross

  • Stephen T. Oh

  • Andrew Perkins

  • Michael F. Leahy

  • Samineh Deheshi

  • Rafe Donahue

  • Barbara J. Klencke

  • Srdan Verstovsek

Medical Centers

  • UT Health San Antonio, San Antonio, TX

  • Clinical Outcomes Solutions, Tucson, AZ

  • Mayo Clinic, Phoenix, AZ

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Canada.

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Queen's University Belfast, Belfast, United Kingdom

  • Hospital Saint Antoine, Paris, France

  • St. Pauls Hospital, University of British Columbia, Vancouver, BC, Canada

  • University of Leipzig, Leipzig, Germany

  • Medical Oncology Department, Hospital Universitario Vall D'Hebron, Barcelona, Spain

  • University of Oxford, Oxford, United Kingdom

  • Royal Adelaide Hospital, Adelaide, Australia

  • Washington University School of Medicine, St. Louis, MO

  • Australian Centre For Blood Diseases, Monash University, Melbourne, Australia

  • University of Western Australia,

  • Perth, WA, Australia

  • Sierra Oncology, Vancouver, BC

  • Sierra Oncology Inc., Vancouver, BC, Canada

  • Sierra Oncology, Inc., Brisbane, CA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

  • Canada

  • United Kingdom

  • France

  • Germany

  • Spain

  • Australia

Companies

  • Clinical Outcomes So

  • Sierra Oncology, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Momelotinib

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01969838

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved